Clarinase Drug Interactions

When administered concomitantly with alcohol, loratadine has no potentiating effects as measured by psychomotor performance studies.
CYP3A4 and CYP2D6 inhibitors have been shown to increase loratadine and desloratadine exposure. However, due to the wide therapeutic index of loratadine, no clinically relevant interactions are expected and none were observed with co-administration of erythromycin, ketoconazole and cimetidine in the conducted clinical trials (see Pharmacology: Pharmacokinetics under Actions).
Concurrent administration of monoamine oxidase inhibitors (reversible or irreversible) and sympathomimetic medicines can cause critical hypertension reactions.
Sympathomimetic medicines may reduce the effect of antihypertensive medicines.
The following combinations are not recommended: Bromocriptine, cabergoline, lisuride, pergolide: risk of vasoconstriction and increase in blood pressure.
Dihydroergotamine, ergotamine, methylergometrine: risk of vasoconstriction and increase in blood pressure.
Reversible and irreversible MAO inhibitor(s): risk of vasoconstriction and increase in blood pressure.
Other vasoconstrictors used as nasal decongestant, by oral or nasal route, (such as phenylpropanolamine, phenylephrine, ephedrine, oxymetazoline, naphazoline): risk of vasoconstriction.
Antacids increase the rate of pseudoephedrine sulphate absorption, kaolin decreases it.
Paediatric population: Interaction studies have only been performed in adults.